Business
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID® Separate single-arm trial will assess safety and efficacy in PAXLOVID®-ineligible subjects, who represent a significant vulnerable population with few available treatment options Top-line data from both trials expected by year-end 2025 NEWTOWN, Pa., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NA
About this update from Traws Pharma, Inc.
[{"type":"image","alt":"Traws Pharma, Inc.","displaySize":"","headline":null,"caption":"Traws Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/b7f59076ee694ac5fc5d681bbcfa7af2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/O38eCot9fjUiIRrtl6lHyg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b7f59076ee694ac5fc5d681bbcfa7af2","width":300,"height":300}},"lazy":false},{"type":"text","content":"Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID®","length":193,"tagName":"p"},{"type":"text","content":"Separate single-arm trial will assess safety and efficacy in PAXLOVID®-ineligible subjects, who represent a significant vulnerable population with few available treatment options","length":178,"tagName":"p"},{"type":"text","content":"Top-line data from both trials expected by year-end 2025","length":56,"tagName":"p"},{"type":"text","content":"NEWTOWN, Pa., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced receipt from the Human Research Ethics Committee (HREC) of approval to proceed with a Phase 2 study to evaluate ratutrelvir, a ritonavir-free treatment in newly diagnosed COVID subjects.","length":474,"tagName":"p"},{"type":"text","content":"“The first trial will enable Traws to compare ratutrelvir, a potential best in class ritonavir-free agent, against the current gold standard, PAXLOVID®. Importantly, in second quarter 2025, Pfizer reported $427 million in sales for PAXLOVID®, representing a 70% increase compared to the same period in the prior year1,” said Iain D. Dukes, MA, DPhil, Interim Chief Executive Officer of Traws Pharma. “This study will evaluate safety, as well as rates of infection, COVID symptoms, disease rebound and incidence of Long COVID. In addition, we will initiate a second trial to evaluate the safety and efficacy of ratutrelvir in PAXLOVID®-ineligible patients, a population at risk for poor outcomes from COVID infection wi...